Total included studies | Used qualitatively | Used in MA | Fills a gap | Confirms findings | Changes conclusion | |
---|---|---|---|---|---|---|
All dossier evidence | 160 | 142 (89%) | 26 (16%) | 72 (45%) | 66 (41%) | 67 (42%) |
Unique studies | 123 | 105 (85%) | 24 (20%) | 57 (46%) | 47 (38%) | 56 (46%) |
Supplemental evidence | 37 | 36 (97%) | 2 (5%) | 15 (41%) | 19 (51%) | 9 (24%) |
By study design | ||||||
Head to head trial | 41 | 32 (78%) | 9 (22%) | 18 (44%) | 15 (37%) | 21 (13%) |
Placebo-controlled trial | 46 | 39 (85%) | 10 (22%) | 23 (50%) | 21 (46%) | 21 (46%) |
Observational study | 28 | 27 (96%) | 0 | 13 (46%) | 5 (18%) | 9 (32%) |
Publication status | ||||||
Published (all) | 95 | 81 (85%) | 18 (19%) | 43 (45%) | 43 (45%) | 37 (39%) |
Unpublished (all) | 65 | 58 (89%) | 8 (12%) | 29 (45%) | 23 (35%) | 29 (45%) |
Unpublished unique studies | 46 | 39 (85%) | 8 (17%) | 22 (48%) | 14 (30%) | 25 (54%) |
Unpublished supplemental | 19 | 19 (100%) | 0 | 7 (37%) | 9 (47%) | 4 (21%) |
Subgroup evidence | 26 | 25 (96%) | 3 (12%) | 15 (58%) | 9 (35%) | 12 (46%) |
DERP phase | ||||||
DERP II | 68 | 62 (91%) | 13 (19%) | 22 (32%) | 32 (47%) | 16 (24%) |
DERP III | 50 | 44 (88%) | 7 (14%) | 28 (56%) | 19 (38%) | 29 (58%) |
DERP IV | 42 | 35 (83%) | 6 (14%) | 22 (52%) | 15 (36%) | 21 (50%) |
Publication status by DERP phase | ||||||
Published | 95 | |||||
DERP II | 55 | 50 (91%) | 9 (16%) | 21 (38%) | 24 (44%) | 15 (27%) |
DERP III | 17 | 14 (82%) | 3 (18%) | 8 (47%) | 9 (53%) | 7 (41%) |
DERP IV | 23 | 17 (74%) | 6 (26%) | 14 (61%) | 10 (43%) | 15 (65%) |
Unpublished | 65 | |||||
DERP II | 13 | 9 (69%) | 4 (31%) | 1 (8%) | 8 (62%) | 1 (8%) |
DERP III | 33 | 30 (91%) | 4 (12%) | 20 (61%) | 10 (30%) | 22 (67%) |
DERP IV | 19 | 19 (100%) | 0 | 8 (42%) | 5 (26%) | 6 (32%) |
Report type | 160 | |||||
Original | 48 | 39 (81%) | 15 (31%) | 19 (40%) | 29 (60%) | 23 (48%) |
Update | 112 | 100 (89%) | 11 (10%) | 53 (47%) | 37 (33%) | 43 (38%) |